Computational Insights into Captopril's Inhibitory Potential Against MMP9 and LCN2 in Bladder Cancer: Implications for Therapeutic Application.

Sanjida Kabir AnnanaJannatul FerdoushFarzia LamiaAyan RoyPallab KarMonisha NandiMaliha KabirAyan Saha

Published in: Cancer informatics (2024)

These discoveries present promising prospects for conducting subsequent validation studies both in vitro and in vivo, with the aim of assessing the suitability of captopril for treating BLCA patients, irrespective of their hypertension status, who exhibit elevated levels of MMP9 and LCN2 expression.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
blood pressure
poor prognosis
prognostic factors
cell migration
patient reported outcomes
current status
risk assessment
patient reported